IMDX Insight Molecular Diagnostics Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1642380 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY520.9%
TTM net income YoY-40.9%
TTM EPS YoY27.5%
Revenue 3-yr CAGR1.0%
Net income 3-yr CAGR—
Margins
Gross margin54.5%
Operating margin-1,392.9%
Net margin-1,380.7%
FCF margin-540.3%
EBITDA margin-1,343.0%
Returns
ROE-23,603.1%
ROA-106.5%
ROIC (approx.)—
Asset turnover0.08x
Leverage & solvency
Liabilities / assets120.9%
Debt / equity—
Current ratio2.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-68.2%
Payout ratio—
Capex / revenue43.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.05M | $1.88M | $1.50M | $958,000 | $2.20M |
| Cost of revenue | $1.75M | $1.05M | $1.00M | $880,000 | $697,000 |
| Gross profit | $2.30M | $740,000 | $413,000 | -$18,000 | $1.42M |
| R&D expense | $15.90M | $9.84M | $9.29M | $7.30M | $5.04M |
| SG&A expense | $10.63M | $10.20M | $11.18M | $21.88M | $22.29M |
| Operating income | -$51.12M | -$61.04M | -$25.14M | -$18.00M | -$53.73M |
| Pretax income | — | -$60.66M | -$24.86M | -$18.61M | -$52.87M |
| Income tax | $0 | $0 | $0 | — | -$9.26M |
| Net income | -$50.22M | -$60.66M | -$27.78M | -$72.90M | -$64.10M |
| EBITDA | -$48.93M | -$59.48M | -$23.46M | -$16.47M | -$52.92M |
| EPS (basic) | -1.65 | -4.66 | -3.75 | -13.25 | -0.72 |
| EPS (diluted) | -1.65 | -4.66 | -3.75 | -13.25 | -0.72 |
| Weighted avg. shares (diluted) | 30.48M | 13.07M | 7.65M | 5.54M | 88,920 |
| Banking | |||||
| Net interest income | -$109,000 | -$84,000 | -$52,000 | -$83,000 | -$209,000 |
| Balance sheet | |||||
| Cash & equivalents | $11.58M | $8.64M | $9.43M | $19.99M | $32.95M |
| Receivables | $1.13M | $1.61M | $484,000 | $2.01M | $1.44M |
| Inventory | $446,000 | $410,000 | — | — | — |
| Current assets | $15.31M | $11.76M | $10.70M | $25.54M | $39.14M |
| PP&E, net | $6.43M | $6.32M | $4.71M | $8.71M | $7.13M |
| Goodwill | — | — | — | — | $18.68M |
| Intangibles | $0 | $14.61M | $56.59M | $61.63M | $61.72M |
| Total assets | $25.76M | $35.08M | $74.89M | $100.09M | $159.56M |
| Current liabilities | $12.07M | $7.28M | $7.19M | $12.11M | $14.12M |
| Total liabilities | $57.22M | $47.35M | $49.30M | $60.50M | $94.35M |
| Shareholders' equity | -$31.46M | -$12.27M | $20.47M | $34.29M | $65.22M |
| Shares outstanding | 28.68M | 17.45M | 8.26M | 5.93M | 92.23M |
| Cash flow statement | |||||
| Operating cash flow | -$22.18M | -$20.69M | -$23.32M | -$45.57M | -$35.94M |
| Capital expenditure | $3.19M | $516,000 | $281,000 | $4.34M | $2.25M |
| Free cash flow | -$25.37M | -$21.20M | -$23.61M | -$49.91M | -$38.19M |
| Investing cash flow | -$3.19M | -$512,000 | -$932,000 | -$4.34M | -$13.96M |
| Financing cash flow | $28.07M | $20.43M | $12.19M | $35.81M | $78.36M |
| Depreciation & amortization | $2.20M | $1.56M | $1.68M | $1.53M | $800,000 |
| Stock-based compensation | $2.22M | $1.75M | $2.76M | $10.04M | $6.84M |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.